Recently we had the chance to collaborate on a couple of long newspaper reports on the expanding field of antiaging biotechs. This is a hot area of research that is rapidly being translated into the formation of biotech companies trying to develop drugs and interventions to tackle age-related diseases. The scientific data strongly supports the possibility of developing this type of drugs, although we are still of course far from having something ready for commercialization.
Nevertheless, we have really moved forward a lot on the knowledge of the molecular bases of aging and some of the proposed therapeutic interventions are advancing at high speed. Senolytics are one of these treatments that have already reached clinical trials and for which there is solid evidence of potential effectiveness. Others, such as partial reprogramming, although very promising and powerful, are still far away from real life application.
You can find these two newspaper reports here: